نتایج جستجو برای: non glycemic benefit of sglt2 inhibitors

تعداد نتایج: 21302088  

2017
Mohsen Mazidi Peyman Rezaie Hong‐Kai Gao Andre Pascal Kengne

BACKGROUND The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of oral hypoglycemic agents. We undertake a systematic review and meta-analysis of prospective studies to determine the effect of SGLT2 on blood pressure (BP) among individuals with type 2 diabetes mellitus. METHODS AND RESULTS PubMed-Medline, Web of Science, Cochrane Database, and Google Scholar databases were searc...

2015
Maka S Hedrington Stephen N Davis

Current recommendations for the management of type 2 diabetes mellitus (T2DM) include patient-centered approach, ie, targeting glycemic control based on patient and disease characteristics. Ten different classes of oral and injectable anti-hyperglycemic agents have been developed for T2DM, including the newest class - sodium-glucose cotransporter 2 (SGLT2) inhibitors. Four members of the class ...

2017
Naoto Katakami Tomoya Mita Hidenori Yoshii Toshihiko Shiraiwa Tetsuyuki Yasuda Yosuke Okada Yutaka Umayahara Hideaki Kaneto Takeshi Osonoi Tsunehiko Yamamoto Nobuichi Kuribayashi Kazuhisa Maeda Hiroki Yokoyama Keisuke Kosugi Kentaro Ohtoshi Isao Hayashi Satoru Sumitani Mamiko Tsugawa Makoto Ohashi Hideki Taki Tadashi Nakamura Satoshi Kawashima Yasunori Sato Hirotaka Watada Iichiro Shimomura

INTRODUCTION Sodium-glucose co-transporter-2 (SGLT2) inhibitors are anti-diabetic agents that improve glycemic control with a low risk of hypoglycemia and ameliorate a variety of cardiovascular risk factors. The aim of the ongoing study described herein is to investigate the preventive effects of tofogliflozin, a potent and selective SGLT2 inhibitor, on the progression of atherosclerosis in sub...

Journal: :Current opinion in nephrology and hypertension 2013
Muralikrishna Gangadharan Komala Usha Panchapakesan Carol Pollock Amanda Mather

PURPOSE OF REVIEW Reabsorption of glucose in the proximal tubule occurs predominantly via the sodium glucose cotransporter 2 (SGLT2). There has been intense interest in this transporter as a number of SGLT2 inhibitors have entered clinical development. SGLT2 inhibitors act to lower plasma glucose by promoting glycosuria and this review aims to outline the effect on the diabetic kidney of this h...

2014
Yasong Lu Steven C. Griffen David W. Boulton Tarek A. Leil

In the kidney, glucose in glomerular filtrate is reabsorbed primarily by sodium-glucose cotransporters 1 (SGLT1) and 2 (SGLT2) along the proximal tubules. SGLT2 has been characterized as a high capacity, low affinity pathway responsible for reabsorption of the majority of filtered glucose in the early part of proximal tubules, and SGLT1 reabsorbs the residual glucose in the distal part. Inhibit...

2015
L. Zanoli A. Granata P. Lentini S. Rastelli P. Fatuzzo F. Rapisarda P. Castellino

SGLT2 inhibitors are new antihyperglycaemic agents whose ability to lower glucose is directly proportional to GFR. Therefore, in chronic kidney disease (CKD) the blood glucose lowering effect is reduced. Unlike many current therapies, the mechanism of action of SGLT2 inhibitors is independent of insulin action or beta-cell function. In addition, the mechanism of action of SGLT2 inhibitors is co...

2017
Jennifer M. Trujillo Wesley A. Nuffer

The efficacy of the sodium-glucose cotransporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, and empagliflozin in reducing hyperglycemia in patients with type 2 diabetes is well documented. In addition, positive effects have been observed with these agents on nonglycemic variables, such as reductions in body weight and blood pressure, which may confer additional health benefits. SGLT2 in...

Journal: :Diabetes care 2016
David E Cummings Francesco Rubino

On behalf of the 48 coauthors from our article reporting the findings and recommendations of the 2nd Diabetes Surgery Summit (DSS-II) (1), we sincerely thank Aberle and Göke (2) for their insightful comments about the consideration of sodium–glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes (T2D) shortly after bariatric/metabolic surgery. The DSS-II was a consensus development...

2015
Paola Fioretto Andrea Giaccari Giorgio Sesti

Although antidiabetic agents have been developed to target one or more of the core defects of type 2 diabetes mellitus (T2DM), many patients do not achieve glycemic goals. Inhibition of the sodium-glucose cotransporter 2 (SGLT2) induces glycosuria, reduces glucose toxicity and improves insulin sensitivity and β-cell function. As the mechanism of action of SGLT2 inhibitors is different from othe...

2017
Keiichi Torimoto Yosuke Okada Kenji Koikawa Yoshiya Tanaka

BACKGROUND Inhibitors of sodium-glucose co-transporter 2 (SGLT2) have immediate glucose-lowering effects by promoting urinary glucose excretion, without altering insulin level. Only a few studies have evaluated blood glucose dynamics in the early period after administration. The present retrospective study was designed to determine the immediate effects of SGLT2 inhibitors on blood glucose dyna...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید